Business
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser
About this update from Procept Biorobotics Corporation
[{"type":"text","content":"Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial\nSAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced its Aquablation therapy was evaluated in the independent, investigator-initiated WATER III trial. This study compared Aquablation therapy to laser enucleation for treating large prostates, with results presented in the prestigious Game-Changer session at the European Association of Urology (EAU) 2025 Annual Congress in Madrid, Spain. WATER III is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation in prostate sizes 80-180mL. The study treated 186 men between December 2020 and September 2024 and reported three-month primary safety and efficacy endpoints and will subsequently follow patients to five years. The three-month results demonstrated that Aquablation therapy delivered substantially similar symptom relief while showing significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%) compared to laser enucleation. Additionally, the procedural transfusion rate in the Aquablation therapy arm was 0%. These findings demonstrate that modern Aquablation therapy techniques are both safe and highly reproducible in managing bleeding risk. \"WATER III represents a significant milestone in our mission to establish Aquablation therapy as the standard of care for patients suffering with BPH,\" said Reza Zadno, CEO of PROCEPT BioRobotics. \"Building on our previous randomized WATER data comparing Aquablation therapy to TURP, WATER III demonstrates that Aquablation therapy delivers compelling clinical outcomes compared to laser enucleation. What makes these results particularly meaningful is Aquablation therapy's ability to deliver effective symptom relief while preserving critical quality of life factors—specifically sexual function and continence. These findings reinforce our dedication to providing treatments that address the complete patient experience.\" “The WATER III results are impressi...